Vitiligo is a common condition that causes skin discoloration in patches and premature graying of the hair on one’s scalp, beard, eyebrows, or eyelashes. It occurs when pigment-producing cells (melanocytes) die or stop producing melanin due to an autoimmune condition, hereditary disorder, or a trigger event. Although it can start at any age, symptoms typically appear before the age of 30. Treatment for vitiligo often involves repigmenting the skin using prescription creams such as Opzelura.

What is Opzelura?
Opzelura (ruxolitinib) cream is an FDA-approved treatment for adolescents and adults with non-segmental vitiligo. It has been proven to scientifically restore pigment in the face and body (up to 10% of the body surface area). It can even be applied around sensitive areas, such as the eyes, mouth, and genitals.

How Opzelura works
In people with vitiligo, the immune system activates the JAK-STAT pathway, an immune signal, to destroy melanin-producing cells, causing a patchy loss of skin color. Opzelura is a unique treatment focusing on this pathway to reduce melanocyte destruction and restore pigmentation.

Using Opzelura
It is best to follow the doctor’s advice when using treatments like Opzelura. One must also take precautionary measures, such as limiting time in direct sunlight, wearing protective clothing in the sun, and using a broad-spectrum sunscreen.

As a topical cream, there is a possibility that Opzelura may interact with one’s personal care and cosmetic products, such as razors, serums, moisturizers, etc. Speak to the doctor regarding the best practices and precautions to take when using this ointment.

When turning to Opzelura as a course of treatment for vitiligo, it is essential to stay consistent. It may take up to 6 months for individuals to see a satisfactory response to their treatment. If there is no repigmentation even after six months, it is best to speak to the doctor and consider other options. To help reduce the overall cost of treatment, the brand also offers a copay savings card for eligible individuals, bringing the cost down to $0 per tube.